Testing the possibility to protect bovine PrPC transgenic Swiss mice against bovine PrPSc infection by DNA vaccination using recombinant plasmid vectors harboring and expressing the complete or partial cDNA sequences of bovine PrPC.
The objective of this study was to investigate the molecular mechanisms of neurobiological processes involved in the degeneration of the central nervous system. The bovine spongiform encephalopathy (BSE) was used as experimental model system for investigation of transmissible spongiform encephalopathy (TSE). The experimental strategy was to evaluate the possibility for protection of bovine PrP(C) transgenic mice against a bovine PrP(Sc) infection by DNA vaccination using the complete or partial cDNA sequences of the bovine prion protein. Three recombinant plasmids pCR3.1-EX-PrP-BSE-C20 (C20), pCR3.1-EX-PrP-BSE-90-235-C4 (C4), and pCR3.1-EX-PrP-BSE-106-131-C14 (C14) were constructed. These mammalian expression vectors harbor complete (C20) or partial (C4 and C14) cDNA sequences of the Bos taurus PrP(C) (BTPrP(C)) encoding for amino acid residues 1-264 (C20), 90-235 (C4), and 106-131 (C14) of the BTPrP(C). Transgenic mice harboring and expressing BTPrP(C) were generated using the donor strain C57/CBA, receptor strain Swiss mouse, and recombinant plasmid MoPrPXho-boPrP. Crossing of positive transgenic mice to bovine PrP and negative to murine PrP with 129/OLA (murine PrP-/-) and C57BL6x129/OLA (murine PrP+/-) mice was carried out to amplify the colony of transgenic mice termed bovine PrP(C) transgenic Swiss mice (BTPrP-TgM). The capabilities of C20, C4, and C14 to express the corresponding cDNA sequence of BTPrP(C) in vitro and in vivo were confirmed prior to DNA vaccination of the BTPrP-TgM using NIH 3T3 cells and BALB/c mice, respectively. In order to prove the capability of the constructed expression vectors to protect BTPrP-TgM in vivo against a BSE infection 80 female BTPrP-TgM were vaccinated intramuscularly and subcutaneously with DNA of the plasmids C20, C4, C14, and parental vector pCR3.1 (100 microg DNA corresponding to about 26-30 pmol DNA/animal and application) in four groups (each consists of 20 animals). DNA vaccination was followed by three additional boosters. The vaccinated animals (15 animals of each group) were challenged twice per oral with homogenates of brain material obtained from BSE cattle containing the infectious PrP(Sc) (100 microl/animal which corresponds to 15 mg of a 15% brain homogenate). The first and second challenge experiments were performed 76-83 and 181 days post DNA vaccination, respectively. A part of the vaccinated animals (3-5 animals of each group) that served as internal negative control were mock infected using the brain homogenate of healthy cattle or Phosphate saline buffer (PBS). A variety of symptoms and clinical pictures were observed during the monitoring of DNA vaccinated animals. However, the observed diseases seem to be similar in all experimental animal groups. After an observation period of 14 months post the second challenge experiment the remaining animals (some animals died or were sacrificed when moribund during the study) were sacrificed after expiration of the experimental schedule. The right hemisphere of the brain and a half of the spleen tissue of the individual animals were used for detection of PrP(Sc) by Western blot analysis. The misfolded bovine PrP(Sc) was not detected in the brain or spleen tissues of those animals that were vaccinated with DNA of C20, which was able to express the complete bovine PrP(C) protein in vitro and in vivo. In contrast, the bovine PrP(Sc) was detected in the brain or spleen tissues of animals that were DNA vaccinated with DNA of the parental vector pCR3.1, with DNA of C4, or with DNA of C14. The results of these studies underline that the constructed expression vector C20 possesses the protective capacity to inhibit the formation of misfolded bovine PrP(Sc) in BTPrP-TgM under the conditions used. A delay of occurrence of TSE-specific symptoms in the majority of the vaccinated animals seems to be due to the prolonged incubation time of BSE infection.
Müller
Sandra
S
Abteilung Virologie, Hygiene-Institut der Universität Heidelberg, Im Neuenheimer Feld 324, 69120, Heidelberg, Germany.
Kehm
Roland
R
Handermann
Michaela
M
Jakob
Nurith J
NJ
Bahr
Udo
U
Schröder
Björn
B
Darai
Gholamreza
G
D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D002417:Cattle; D018076:DNA, Complementary / Q000235:genetics; D005260:Female; D015870:Gene Expression; D005822:Genetic Vectors; D066298:In Vitro Techniques; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D041681:NIH 3T3 Cells; D010957:Plasmids / Q000235:genetics; D018621:PrPC Proteins / Q000235:genetics* / Q000276:immunology*; D018620:PrPSc Proteins / Q000472:pathogenicity*; D017096:Prion Diseases / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D019444:Vaccines, DNA / Q000235:genetics* / Q000494:pharmacology*
D018076:DNA, Complementary; D018621:PrPC Proteins; D018620:PrPSc Proteins; D019444:Vaccines, DNA
Science. 1994 Apr 22;264(5158):530-1
7909169
Philos Trans R Soc Lond B Biol Sci. 1994 Mar 29;343(1306):447-63
7913765
Arch Virol Suppl. 2000;(16):75-86
11214936
Nat Med. 2000 Mar;6(3):258-9
10700223
Nature. 1970 Aug 15;227(5259):680-5
5432063
Acta Neurobiol Exp (Wars). 2002;62(3):141-7
12416391
Drug Discov Today. 2002 Sep 15;7(18):936-7
12546861
Curr Opin Struct Biol. 1997 Feb;7(1):53-9
9032055
Virology. 2004 Jan 5;318(1):112-22
14972540
Science. 1998 Nov 6;282(5391):1079-83
9804539
Int J Exp Pathol. 1996 Dec;77(6):283-93
9155663
J Gen Virol. 1991 Jan;72 ( Pt 1):201-4
1671225
Nat Med. 1997 May;3(5):491-2
9142109
Neuron. 2000 Aug;27(2):399-408
10985358
J Neuroimmunol. 2002 Nov;132(1-2):113-6
12417440
Science. 2001 Oct 5;294(5540):178-82
11546838
Arch Neurol. 2000 Dec;57(12):1695-702
11115235
Nature. 1997 Nov 6;390(6655):74-7
9363892
Curr Opin Neurobiol. 1996 Oct;6(5):651-60
8937830
Nature. 1995 Dec 21-28;378(6559):779-83
8524411
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15137-42
10611351
Brain Pathol. 1998 Oct;8(4):715-33
9804380
Transgenic Res. 2002 Dec;11(6):547-64
12509129
Hum Mol Genet. 1997;6(10):1699-705
9300662
Adv Virus Res. 2001;56:277-311
11450303
Nature. 1996 Jul 11;382(6587):180-2
8700211
Annu Rev Microbiol. 1994;48:655-86
7826022
Philos Trans R Soc Lond B Biol Sci. 1994 Mar 29;343(1306):415-23
7913760
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2520-5
9482918
J Toxicol Sci. 2002 May;27(2):69-77
12058449
Cell. 1999 Mar 19;96(6):869-78
10102274
Eur J Biochem. 1998 Jan 15;251(1-2):462-71
9492319
Anal Biochem. 1996 Sep 5;240(2):306-8
8811928
J Mol Med (Berl). 1996 Mar;74(3):111-26
8846161
Genet Anal. 1996 Dec;13(6):159-63
9117892
Nucleic Acids Res. 1997 Dec 15;25(24):4876-82
9396791
Arch Virol. 2003 Apr;148(4):677-91
12664293
Gene. 1988 Dec 15;73(1):237-44
3243435
Trends Biochem Sci. 2002 Jun;27(6):301-7
12069790
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5690-4
7911243
EMBO J. 2002 Dec 2;21(23):6358-66
12456643
J Mol Biol. 1990 Oct 5;215(3):403-10
2231712
Curr Neurol Neurosci Rep. 2002 Sep;2(5):457-64
12169227
Expert Rev Vaccines. 2004 Jun;3(3):279-90
15176944
Dev Biol Stand. 1993;80:31-44
8270114
Bioinformatics. 2002 Jun;18(6):880-3
12075024
J Immunol Methods. 1996 Dec 15;199(2):109-18
8982352
Trends Genet. 1997 Jul;13(7):264-9
9242048
Dev Biol (Basel). 2001;106:455-9; discussion 460-1, 465-75
11761262
Nature. 2001 Aug 16;412(6848):739-43
11507642
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9295-9
11470893
Virology. 1997 Apr 14;230(2):207-16
9143276
Neuron. 1998 Dec;21(6):1339-51
9883727
Virus Genes. 2002 Oct;25(2):159-67
12418451
Nature. 1980 Jan 10;283(5743):216-8
7350544
J Infect Dis. 1993 Mar;167(3):602-13
8440932
Am J Pathol. 1995 Apr;146(4):785-811
7717447
Mol Neurobiol. 1994 Apr-Jun;8(2-3):121-7
7999308
Science. 1982 Apr 9;216(4542):136-44
6801762
Nature. 2003 Oct 16;425(6959):717-20
14562104
Virology. 2004 Mar 30;321(1):1-7
15033559
Biochem Cell Biol. 2001;79(5):613-28
11716303
Science. 1997 Oct 10;278(5336):245-51
9323196
Nature. 1997 Oct 2;389(6650):498-501
9333239
Nucleic Acids Res. 1999 Jan 1;27(1):215-9
9847184
Med Hypotheses. 1998 Jul;51(1):17-22
9881831
Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7139-43
7913747
Prog Clin Biol Res. 1989;317:659-67
2574875
Br Med Bull. 2003;66:199-212
14522860